Marshall Wace
FATE icon

Marshall Wace’s Fate Therapeutics FATE Stock Holding History

Marshall Wace’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.33M Buy
+492,426
New +$911K ﹤0.01% 2061
2025
Q2 		– Sell
-19,155
Closed -$15.1K – 2848
2025
Q1 		$15.1K Sell
19,155
-493,486
-96% -$605K ﹤0.01% 2566
2024
Q4 		$846K Buy
+512,641
New +$1.29M ﹤0.01% 1811
2024
Q3 		– Sell
-330,082
Closed -$1.08M – 2642
2024
Q2 		$1.08M Sell
330,082
-15,355
-4% -$67.2K ﹤0.01% 1653
2024
Q1 		$2.54M Buy
+345,437
New +$2.14M ﹤0.01% 1247
2022
Q1 		– Sell
-74,622
Closed -$4.37M – 3533
2021
Q4 		$4.37M Sell
74,622
-103,716
-58% -$5.88M 0.01% 1464
2021
Q3 		$10.6M Buy
178,338
+127,195
+249% +$9.98M 0.04% 524
2021
Q2 		$4.44M Buy
+51,143
New +$4.12M 0.02% 915
2021
Q1 		– Sell
-68,278
Closed -$6.21M – 2584
2020
Q4 		$6.21M Buy
+68,278
New +$4.24M 0.03% 495
2020
Q1 		– Sell
-16,273
Closed -$318K – 1762
2019
Q4 		$318K Buy
+16,273
New +$258K ﹤0.01% 1261

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Marshall Wace's FATE Position: Q2 2026 in Review

Marshall Wace opened a new position in Fate Therapeutics (FATE) in Q2 2026: 492,426 shares worth $1.33M. The stake represents ﹤0.01% of the portfolio and ranks #2061 among its holdings. This is a return to the name: Marshall Wace previously reported a position in FATE as recently as Q1 2025.

Marshall Wace first reported a position in FATE in Q4 2019 and has held it in 10 quarters since. The position peaked at $10.6M in Q3 2021. 156 funds tracked by Wall St. Rank hold FATE as of Q2 2026.

  • Marshall Wace held 492,426 shares of Fate Therapeutics worth $1.33M as of Q2 2026.
  • Fate Therapeutics was a new Marshall Wace position in Q2 2026.
  • Fate Therapeutics made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #2061 holding.
  • Marshall Wace first reported a position in Fate Therapeutics in Q4 2019 and has held it in 10 quarters since.
  • Marshall Wace's Fate Therapeutics position peaked at $10.6M in Q3 2021.
  • 156 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.